MID-VOLUME · FEMALE-LED
abaloparatide Side Effects
abaloparatide (also sold as Tymlos) sits MID-VOLUME #211 of 524 by FAERS report count. Lead signal: FEMALE-LED - 95% of sex-coded reports are female (22,772 F / 1,168 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 24,667
- FAERS reports
FDA Adverse Event Reporting System extract for abaloparatide. Stamp set WATCHLIST · DEATH-MARKED · HOSP-LIGHT. How figures are compiled.
abaloparatide reporting skew - 95% of sex-coded reports are female (22,772 F / 1,168 M). Volume band MID-VOLUME #211 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for abaloparatide (Tymlos) (24,667 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2015–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
HEADACHE leads 4,180 of 24,667 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (95% of sex-coded rows)
Age peak 45-64 (4,118 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 266 reports (1.1% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 206 |
| PNEUMONIA | 11 |
| CARDIAC FAILURE CONGESTIVE | 7 |
| RESPIRATORY FAILURE | 5 |
| SEPSIS | 5 |
| CEREBROVASCULAR ACCIDENT | 4 |
| FALL | 4 |
| MYOCARDIAL INFARCTION | 4 |
| COVID-19 | 3 |
| ENCEPHALOPATHY | 3 |
| HIP FRACTURE | 3 |
| LIVER DISORDER | 3 |
| RESPIRATORY DISTRESS | 3 |
| THROMBOSIS | 3 |
| URINARY TRACT INFECTION | 3 |
| ACUTE KIDNEY INJURY | 2 |
| AORTIC DISSECTION | 2 |
| ATRIAL FIBRILLATION | 2 |
| CARDIAC ARREST | 2 |
Reactions in Hospitalization Reports
Hospitalization is lighter here (1,677). Reactions in that subset:
| Reaction | Reports |
|---|---|
| FALL | 201 |
| HOSPITALISATION | 126 |
| DIZZINESS | 119 |
| INTENTIONAL DOSE OMISSION | 110 |
| HEADACHE | 106 |
| NAUSEA | 103 |
| PNEUMONIA | 98 |
| FATIGUE | 86 |
| THERAPY INTERRUPTED | 81 |
| PRODUCT DOSE OMISSION | 65 |
| PAIN | 64 |
| ARTHRALGIA | 57 |
| HIP FRACTURE | 57 |
| PALPITATIONS | 56 |
| URINARY TRACT INFECTION | 54 |
| ATRIAL FIBRILLATION | 53 |
| CEREBROVASCULAR ACCIDENT | 51 |
| BACK PAIN | 49 |
| VOMITING | 47 |
How to read abaloparatide FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-LIGHT)
FAERS holds 24,667 voluntary reports linked to abaloparatide (Tymlos), 2015-2025. Death is listed on 266 (1.1%). Hospitalization appears on 1,677 (6.8%). Top co-reported indication: Osteoporosis Postmenopausal.
Mid-volume extract - treat DEATH-MARKED · HOSP-LIGHT as signal-detection rates next to 95% of sex-coded reports are female (22,772 F / 1,168 M).
Read with abaloparatide
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-LIGHT stamps.
ABS(total_reports) peer at 24,883 FAERS cases (Δ 216 heavier vs abaloparatide); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 24,428 FAERS cases (Δ 239 lighter vs abaloparatide); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 24,367 FAERS cases (Δ 300 lighter vs abaloparatide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(total_reports) peer at 24,979 FAERS cases (Δ 312 heavier vs abaloparatide); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's WATCHLIST · DEATH-MARKED · HOSP-LIGHT · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 61.0 pp vs abaloparatide's DEATH-MARKED): CASELOAD · HOSP-MID.
abaloparatide stamps WATCHLIST · FEMALE-LED; class peers and methodology beat restating the same FAERS caveats on every effects URL.